Ποια είναι η τιμή για Scilex Holding Company (SCLX)

Η τιμή για Scilex Holding Company (SCLX) είναι $5.61

Ποια είναι η κεφαλαιοποίηση αγοράς για Scilex Holding Company (SCLX)

Η κεφαλαιοποίηση αγοράς για Scilex Holding Company (SCLX) είναι $47.65M

Scilex Holding Company (SCLX) Τιμή και Κεφαλαιοποίηση Αγοράς

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Η τιμή για SCLX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$619,084 $47.65M	NVDA	$5.257T	+11,032,700.31%
$541,569 $47.65M	AAPL	$4.599T	+9,651,306.37%
$483,620 $47.65M	GOOG	$4.107T	+8,618,578.40%
$421,282 $47.65M	MSFT	$3.577T	+7,507,649.18%
$330,608 $47.65M	AMZN	$2.807T	+5,891,723.17%

Η τιμή για SCLX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$619,084 $47.65M